Upgrade to SI Premium - Free Trial

Intellia Therapeutics (NTLA) Reiterated at Market Outperform by Citizens on HAE Opportunity

September 8, 2026 4:25 AM
Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $30.00 price target on Intellia Therapeutics (NASDAQ: NTLA).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments